These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 863294)

  • 1. Impaired fibrin formation in advanced cirrhosis.
    Dettori AG; Ponari O; Civardi E; Megha A; Pini M; Poti R
    Haemostasis; 1977; 6(2):137-48. PubMed ID: 863294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal fibrin polymerization in liver disease.
    Green G; Thomson JM; Dymock IW; Poller L
    Br J Haematol; 1976 Nov; 34(3):427-39. PubMed ID: 186092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fibrinogen and fibrin structure in patients with cirrhosis of the liver (author's transl)].
    Klingemann HG; Brunswig D; Liehr H
    Z Gastroenterol; 1978 Sep; 16(9):564-73. PubMed ID: 706517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenemia.
    Regañón E; Vila V; Aznar J; Garrido G; Estellés A; Berenguer J
    Thromb Res; 1987 Jun; 46(5):705-14. PubMed ID: 3629544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysfibrinogenemia associated with liver disease.
    Palascak JE; Martinez J
    J Clin Invest; 1977 Jul; 60(1):89-95. PubMed ID: 874092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemostatic Profiles are Similar across All Aetiologies of Cirrhosis.
    Bos S; van den Boom B; Kamphuisen PW; Adelmeijer J; Blokzijl H; Schreuder T; Lisman T
    Thromb Haemost; 2019 Feb; 119(2):246-253. PubMed ID: 30609442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysfibrinogen Kagoshima with the amino acid substitution gammaThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule.
    Niwa K; Mimuro J; Miyata M; Sugo T; Ohmori T; Madoiwa S; Tei C; Sakata Y
    Thromb Res; 2008; 121(6):773-80. PubMed ID: 17854865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of standard fibrinogen measurement methods with fibrin clot firmness assessed by thromboelastometry in patients with cirrhosis.
    Vucelic D; Jesic R; Jovicic S; Zivotic M; Grubor N; Trajkovic G; Canic I; Elezovic I; Antovic A
    Thromb Res; 2015 Jun; 135(6):1124-30. PubMed ID: 25900310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test.
    Hawiger J; Niewiarowski S; Gurewich V; Thomas DP
    J Lab Clin Med; 1970 Jan; 75(1):93-108. PubMed ID: 4243578
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of fibrinogen-fibrin degradation products by counterelectrophoresis.
    Brody JI
    J Clin Pathol; 1972 Sep; 25(9):754-6. PubMed ID: 5086217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring plasma fibrinogen levels in patients with liver cirrhosis. The occurrence of proteolytic fibrin(ogen) degradation products and their influence on several fibrinogen assays.
    de Maat MP; Nieuwenhuizen W; Knot EA; van Buuren HR; Swart GR
    Thromb Res; 1995 May; 78(4):353-62. PubMed ID: 7631315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of simple coagulation tests (fibrinogen assays and thrombin coagulase clotting time) in the diagnosis of liver cancer.
    Pengo V; Levi Minzi S; Dal Bo Zanon R; Cappellato G; Farinati F; Girolami A
    J Med; 1984; 15(2):149-60. PubMed ID: 6096471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
    Konieczynska M; Fil K; Bazanek M; Undas A
    Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fibrinolysis in chronic liver diseases studied by in vitro blood coagulation tests].
    Pósán E; Tornai I; Udvardy M
    Orv Hetil; 1994 Dec; 135(51):2821-4. PubMed ID: 7838517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired dysfibrinogenaemia in acute and chronic liver disease.
    Lane DA; Scully MF; Thomas DP; Kakkar VV; Woolf IL; Williams R
    Br J Haematol; 1977 Feb; 35(2):301-8. PubMed ID: 870000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive roles of platelets and fibrinogen in whole-blood fibrin clot formation upon dilution as assessed by thromboelastometry.
    Ninivaggi M; Feijge MA; Baaten CC; Kuiper GJ; Marcus MA; Ten Cate H; Lancé MD; Heemskerk JW; van der Meijden PE
    Thromb Haemost; 2014 Mar; 111(3):447-57. PubMed ID: 24258426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Circulating levels of products of fibrinogen and fibrin monomer degradation in liver cirrhosis].
    Rocha E; López Borrasca A
    Rev Med Univ Navarra; 1974; 18(3-4):143-7. PubMed ID: 4471076
    [No Abstract]   [Full Text] [Related]  

  • 18. [Diagnostic significance of proteolytic breakdown products of fibrinogen and fibrin].
    Heene DL; Genth K
    Internist (Berl); 1984 Feb; 25(2):93-101. PubMed ID: 6231262
    [No Abstract]   [Full Text] [Related]  

  • 19. A naturally occurring antibody that inhibits fibrin polymerization.
    Hoots WK; Carrell NA; Wagner RH; Cooper HA; McDonagh J
    N Engl J Med; 1981 Apr; 304(15):857-61. PubMed ID: 7207522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin clotting time and fibrin polymerization in liver cirrhosis.
    Szczepański M; Habior A; Szczepanik A; Soszka A; Grel K
    Mater Med Pol; 1994; 26(3):87-90. PubMed ID: 7603083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.